Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCL9 | O00512 | 10/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 10/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.33 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23685122 | 1.00 | NAMPT (0.37) | NAMPTABL1BCL9CTNNB1CYP11B1 | |
| SCHEMBL23717133 | 0.89 | SLC5A7 (0.36) | NAMPT | |
| SCHEMBL23683773 | 0.84 | AR (0.35) | — | |
| SCHEMBL23700520 | 0.84 | NAMPT (0.35) | NAMPTABL1BCL9CTNNB1CYP11B1 | |
| SCHEMBL23700518 | 0.84 | NAMPT (0.35) | NAMPTABL1BCL9CTNNB1CYP11B1 | |
| SCHEMBL23700517 | 0.84 | NAMPT (0.35) | NAMPTABL1BCL9CTNNB1CYP11B1 | |
| SCHEMBL23685153 | 0.83 | SLC5A7 (0.37) | BCL9CTNNB1GABRA5 | |
| SCHEMBL23717106 | 0.83 | SLC5A7 (0.37) | BCL9CTNNB1GABRA5 | |
| SCHEMBL23717097 | 0.82 | NAMPT (0.36) | NAMPTABL1BCL9CTNNB1CYP11B1 | |
| SCHEMBL23683780 | 0.81 | BCL9 (0.37) | BCL9CTNNB1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | NAMPT 224/4885ABL1 2734/4885BCL9 4122/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | NAMPT 224/4885ABL1 2734/4885BCL9 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.